newsfilter
← Latest News
Business Wire·

Dicerna Announces FDA Acceptance of Lilly's Investigational New Drug (IND) Application for LY3819469

– Second GalXC™ RNAi Investigational New Drug (IND) Application Filed by Lilly Under Companies' Global Research Collaboration and Licensing Agreement – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading develope